MC

542.3

+0.31%↑

SANES

8.79

-0.35%↓

SAF

305.6

+0.69%↑

BBVA

16.46

-0.18%↓

BNP

78.2

-0.1%↓

MC

542.3

+0.31%↑

SANES

8.79

-0.35%↓

SAF

305.6

+0.69%↑

BBVA

16.46

-0.18%↓

BNP

78.2

-0.1%↓

MC

542.3

+0.31%↑

SANES

8.79

-0.35%↓

SAF

305.6

+0.69%↑

BBVA

16.46

-0.18%↓

BNP

78.2

-0.1%↓

MC

542.3

+0.31%↑

SANES

8.79

-0.35%↓

SAF

305.6

+0.69%↑

BBVA

16.46

-0.18%↓

BNP

78.2

-0.1%↓

MC

542.3

+0.31%↑

SANES

8.79

-0.35%↓

SAF

305.6

+0.69%↑

BBVA

16.46

-0.18%↓

BNP

78.2

-0.1%↓

Search

Grifols SA

Cerrado

SectorFinanzas

12.62 1.57

Resumen

Variación precio

24h

Actual

Mínimo

12.425

Máximo

12.865

Métricas clave

By Trading Economics

Ingresos

57M

117M

Ventas

-85M

1.9B

P/B

Media del Sector

28.011

28.015

BPA

0.19

Rentabilidad por dividendo

1.22

Margen de beneficios

6.19

Empleados

23,833

EBITDA

-135M

347M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+8.61% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.22%

3.82%

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.6B

7.4B

Apertura anterior

11.05

Cierre anterior

12.62

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

190 / 530 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Grifols SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 abr 2025, 17:19 UTC

Adquisiciones, fusiones, absorciones

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 abr 2025, 13:02 UTC

Adquisiciones, fusiones, absorciones

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 abr 2025, 10:13 UTC

Adquisiciones, fusiones, absorciones

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

28 jul 2025, 10:51 UTC

Charlas de Mercado

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

15 abr 2025, 09:55 UTC

Charlas de Mercado

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2 abr 2025, 09:27 UTC

Acciones populares

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Comparación entre iguales

Cambio de precio

Grifols SA previsión

Precio Objetivo

By TipRanks

8.61% repunte

Estimación a 12 Meses

Media 13.5 EUR  8.61%

Máximo 15 EUR

Mínimo 12 EUR

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Grifols SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

1

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 8.566Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

190 / 530 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
help-icon Live chat